Description
Ciglitazone is a thiazolidinedione that exhibits antihypertensive, anticancer, and anti-diabetic activities. Ciglitazone acts as an agonist at PPARγ receptors, decreasing insulin levels, VEGF production, and blood pressure. In cellular models of stomach cancer, ciglitazone induces G1 phase cell cycle arrest, inhibits ERK phosphorylation, and suppresses cell growth.